Joint Working Agreement - Executive Summary

1. Project Name:	**'Diabetes Self-check'** Educational patient app for the monitoring of lipohypertrophy & lipoatrophy
2. Organisations involved with this Joint Working Project are:	**Lilly UK** **Swansea Bay University Health Board**
3. The objectives for this project are:	Development of a digital application which will give detailed instructions to patients through illustrations, text and videos on how to carry out an injection site self-examination. To be used by insulin dependent patients with diabetes, to support remote consultations with their healthcare provider. The project will also develop a clinic protocol for the use of the app pre, during and post a remote consultation. This will become part of standard clinical practice both during and after the Covid pandemic. The app will not only support the NHS Covid response strategies of reducing in-person consultations through the use of digital solutions, and protecting those patients most clinically at risk from Covid-19 (such as people with diabetes), but will continue to benefit patients post the Covid pandemic by reducing the need of attending diabetes reviews in person in a healthcare setting.
4. Roles and Responsibilities, including any funding	**Lilly UK** • Development of Joint Working Agreement documentation and certification of documentation. • Project management including developing a project plan, with roles and responsibilities of all organisations, and timelines for delivery. • Supporting a pilot of the app, including data analysis and seeking to gain feedback from relevant patient organisations.(Pilot planned to be carried out with either Diabetes UK Wales, od the Swansea Uni expert patient group, with a minimum of 3 patients, over a maximum period of 1 month). • Wider implementation of the app across other NHS organisations. Provide guidance on applying for inclusion on the NHS app store • Funding for app development, launch and maintenance. *At no point will this data provide Lilly with any identifiable patient data. **Swansea Bay University Health Board** • Understanding of the Swansea Bay University Health board internal process for working collaboratively with Lilly UK, including any ethics or governance approvals needed and the facility for receiving funding. • Joint maintenance of a project and actions plan. • Availability for regular project meetings. • Development of a clinic protocol incorporating the new app • Development of the app content.

Joint Working Agreement - Executive Summary

	• Commissioning Swansea University to develop app content and illustrations. • Organising pilot through expert patient panel as required. • Commitment to measure outcomes as per section 3. • Ongoing app maintenance for a minimum of 3 years. **Funding** Total project costs approx. £14701.08 NHS Swansea total contribution approx. £6,124.69 Lilly UK total contribution approx. £8576.39
5. The expected benefits for patients on delivery of this project are:	Improvement in self-examination and management leading to: • Reduction in lipohypertrophy & lipoatrophy. • Reduction in erratic insulin absorption related to lipohypertrophy and therefore an improvement in glycaemic control and time in range. Reduction in practice-based appointments, therefore reducing clinic exposure and saving patients unnecessary trips to their GP practice or hospital for in person diabetes reviews.
6. The expected benefits for the partner organisation(s) on delivery of this project are:	• Preventing poor control which can be caused by lipohypertrophy will reduce the need for clinical management associated with poor glycaemic control and the associated hyperglycaemia and hypoglycaemia, along with severe injection site reactions. • Reduction in number of surgery attendances may lead to improved efficiency within healthcare settings.
7. The expected benefits for Lilly UK on delivery of this are:	Eli Lilly manufactures and sells insulins and other diabetes medications. Reducing and / or management of side effects associated with insulin administration helps to ensure that patients prescribed Lilly insulins have the best possible clinical outcomes. As part of routine clinical medication reviews this project may lead to an increase in the prescribing of Lilly medications in line with the existing local formulary and NICE guidelines. This project will demonstrate partnership working between Lilly and the NHS which will be replicable elsewhere. The collection of patient feedback through this project may provide real-world evidence around the improved management of patients on insulins in relation to injection site reactions. Lilly will seek to publish outcomes from the project in relevant trade or clinical press.